CLINICAL_TRIALS ClinicalTrials.gov record update

A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07254793
Title field or adapter rule: {'original_value': 'A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:29.314014+00:00
Published At: 2026-10-29T00:00:00+00:00
Record Updated At: 2026-10-29
Source Retrieved At: 2026-10-31T22:18:11.341859+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Acute Lymphoid Leukemia", "Acute Myeloid Leukemia", "Acute Undifferentiated Leukemia (AUL)", "Myelodysplastic Syndrome", "Chronic Myeloid Leukemia", "Non-Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-29", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07254793"
protocolSection.identificationModule.officialTitle: "A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Prophylactic DLI-X Arm'], 'description': "Pro-DLI-X will be given through the patient's central line at an initial dose of 100,000 CD3+ cells/kilogram (kg) of recipient weight for haploidentical hematopoietic cell transplantation (haploHCT) and 300,000 CD3+ cells/kg for matched sibling donor hematopoietic cell transplantation (MSD HCT). Participants will receive up to 3 doses of pro-DLI-X, and each dose will be increased as follows: dose 2 will be 300,000 CD3+ cells/kg for haploHCT and 1,000,000 CD3+ cells/kg for MSD HCT; dose 3 will be 1,000,000 CD3+ cells/kg for haploHCT and 3,000,000 CD3+ cells/kg for MSD HCT.", 'name': 'Exercise Mobilized Prophylactic DLI', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Prophylactic Standard DLI Arm'], 'description': "Pro-DLI will be given through the patient's central line at an initial dose of 100,000 CD3+ cells/kilogram (kg) of recipient weight for haploidentical hematopoietic cell transplantation (haploHCT) and 300,000 CD3+ cells/kg for matched sibling donor hematopoietic cell transplantation (MSD HCT). Participants will receive up to 3 doses of pro-DLI-X, and each dose will be increased as follows: dose 2 will be 300,000 CD3+ cells/kg for haploHCT and 1,000,000 CD3+ cells/kg for MSD HCT; dose 3 will be 1,000,000 CD3+ cells/kg for haploHCT and 3,000,000 CD3+ cells/kg for MSD HCT.", 'name': 'Standard Prophylactic DLI', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.